Falsified Medical Product Alert N°3/2019
ICLUSIG (ponatinib) 45mg: falsified product alert
WHO issued this alert after learning on 18 February 2019 that a wholesaler in Malaysia had bought two falsified batches of ICLUSIG, a leukaemia medicine, which reached patients. It follows Alert N°2/2019, in which samples contained paracetamol instead of ponatinib.1
- Issued
- 21 February 2019
- Issued by
- World Health Organization
- Name stated on packaging
- Packaging bears the ICLUSIG brand. WHO did not name the company shown on the falsified packs.
- Genuine manufacturer's statement
- WHO said TAKEDA and INCYTE confirmed they did not manufacture or supply the products and that the batch numbers do not correspond to genuine records.
- Countries where detected
- Malaysia
Batches named in the alert
PR072875 (English packaging), PR0834170 (German packaging)
Advice as stated
Do not use the listed products. Anyone who has taken them or had an adverse event or lack of efficacy should seek advice from a health professional and report it to the national authorities. Obtain medical products only from authentic and reliable sources.
Names printed on falsified products are not evidence that the named company made them. Where WHO or a regulator reports the genuine manufacturer's statement, it is shown.
Sources
- World Health Organization, Medical Product Alert N°3/2019: Falsified ICLUSIG (Asia and globally) (21 February 2019)